论文部分内容阅读
目的探讨沐舒坦联合普米克令舒(布地奈德)、可比特(复方异丙托溴铵)雾化吸入治疗慢性阻塞性肺病急性加重期(AECOPD)的临床疗效。方法 80例患者随机分为治疗组和对照组各40例。治疗组在常规治疗的基础上加沐舒坦30mg联合普米克令舒1mg、可比特2.5ml,生理盐水5 ml稀释后氧气驱动雾化吸入,1日2次,对照组在常规的基础上加普米克令舒1mg、可比特2.5ml,生理盐水5 ml稀释后氧气驱动雾化吸入,每日2次,两组治疗后对临床症状,体征改善时间,实验室检查,肺功能及动脉血气进行比较。结果治疗前两组各项观察指标无差异,(P>0.05),治疗后治疗组在临床症状、体征改善时间,实验室检查,肺功能及动脉血气结果与对照组比较有显著好转,差异有统计学意义(P<0.05)。结论沐舒坦联合普米克令舒、可比特雾化吸入治疗(AECOPD)有显著疗效,且方便、简单、安全、值得推广使用。
Objective To investigate the clinical efficacy of mucosolvan combined with pulmicort and budesonide in the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods 80 patients were randomly divided into treatment group and control group of 40 cases. The treatment group on the basis of conventional treatment plus mucosolvan 30mg combined pulmicort 1mg, comparable bit 2.5ml, 5 ml of saline diluted aerosol inhalation inhalation, on the 1st 2 times, the control group on a regular basis, Ketofen 1mg, bit 2.5ml, saline diluted 5 ml inhaled aerosol inhalation, 2 times a day, after treatment, the clinical symptoms, signs of improvement, laboratory tests, lung function and arterial blood gas were compared . Results There was no significant difference between the two groups before treatment (P> 0.05). After treatment, the clinical symptoms, signs, time of improvement, laboratory test, pulmonary function and arterial blood gas were significantly improved in the treatment group compared with the control group Statistical significance (P <0.05). Conclusion Mucosolvan combined with Pulmicort respules and Atoxic inhalation therapy (AECOPD) has a significant curative effect, and is convenient, simple and safe and should be widely used.